Elanco Reports Q3 2026 Revenue of $1.265 Billion, Updates Outlook
Elanco reported revenue up 11% year over year and 9% organic constant currency growth. Adjusted net income was $136 million, adjusted EPS was $0.27 and adjusted EBITDA was $243 million at a 19.5% margin. The company also provided Q4 2026 guidance, updated its 2026 outlook and issued an initial 2027 outlook.
Elanco Animal Health reported third quarter 2026 revenue of $1.265 billion, representing an 11% year-over-year increase and 9% organic constant currency growth. The company posted a reported net income of $18 million and an adjusted net income of $136 million, with an adjusted EPS of $0.27, which exceeded analyst expectations. Adjusted EBITDA reached $243 million with a margin of 19.5%. Alongside these results, Elanco provided fourth quarter 2026 guidance, updated its full-year 2026 outlook, and shared an initial financial outlook for the full year 2027.
CEO Jeff Simmons characterized the results as evidence of the company's consistent growth and accelerating cash flow.